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Abstract
Circadian rhythms in physiology and behavior are coordinated by the brain’s dominant circadian pacemaker located in the
suprachiasmatic nuclei (SCN) of the hypothalamus. Vasoactive intestinal polypeptide (VIP) and its receptor, VPAC2, play
important roles in the functioning of the SCN pacemaker. Mice lacking VPAC2 receptors (Vipr2
2/2) express disrupted
behavioral and metabolic rhythms and show altered SCN neuronal activity and clock gene expression. Within the brain, the
SCN is not the only site containing endogenous circadian oscillators, nor is it the only site of VPAC2 receptor expression;
both VPAC2 receptors and rhythmic clock gene/protein expression have been noted in the arcuate (Arc) and dorsomedial
(DMH) nuclei of the mediobasal hypothalamus, and in the pituitary gland. The functional role of VPAC2 receptors in rhythm
generation and maintenance in these tissues is, however, unknown. We used wild type (WT) and Vipr22/2mice expressing a
luciferase reporter (PER2::LUC) to investigate whether circadian rhythms in the clock gene protein PER2 in these extra-SCN
tissues were compromised by the absence of the VPAC2 receptor. Vipr2
2/2 SCN cultures expressed significantly lower
amplitude PER2::LUC oscillations than WT SCN. Surprisingly, in Vipr22/2 Arc/ME/PT complex (Arc, median eminence and pars
tuberalis), DMH and pituitary, the period, amplitude and rate of damping of rhythms were not significantly different to WT.
Intriguingly, while we found WT SCN and Arc/ME/PT tissues to maintain a consistent circadian phase when cultured, the
phase of corresponding Vipr22/2 cultures was reset by cull/culture procedure. These data demonstrate that while the main
rhythm parameters of extra-SCN circadian oscillations are maintained in Vipr22/2 mice, the ability of these oscillators to
resist phase shifts is compromised. These deficiencies may contribute towards the aberrant behavior and metabolism
associated with Vipr22/2 animals. Further, our data indicate a link between circadian rhythm strength and the ability of
tissues to resist circadian phase resetting.
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Introduction
It is now well-established that the main mammalian circadian
pacemaker is localized to the suprachiasmatic nucleus (SCN;
[1,2]). The SCN controls the daily timing of behavioral and
physiological processes such as rodent wheel-running and plasma
corticosterone [3]. Such intrinsic timekeeping emerges through the
synchronized activities of several thousand SCN neurons which
themselves function as cell autonomous circadian oscillators [4,5].
The neuropeptide vasoactive intestinal polypeptide (VIP) is
synthesized by neurons in the ventral aspect of the SCN [6,7],
while its cognate receptor, VPAC2, is expressed by many neuronal
cell types in this structure [8,9]. Pharmacological studies in wild-
type rodents have implicated VIP-VPAC2 signaling in the resetting
of the SCN pacemaker by light [10,11] and in setting pacemaker
period [12], but the development of transgenic mouse models with
impaired VIP-VPAC2 expression has revealed a more fundamen-
tal role of this signaling pathway.
Mice deficient in VIP (VIP2/2) or lacking VPAC2 receptor
expression (Vipr22/2) have disrupted circadian rhythms in wheel-
running activity, body temperature and sleep, as well as metabolic,
cardiovascular, cognitive and endocrine dysfunction [13–24].
Such alterations in whole animal behavior and physiology are
accompanied by reductions in the synchrony and amplitude of
electrical and molecular oscillations of SCN neurons [25–29].
Collectively, these studies establish that VIP-VPAC2 signaling is
necessary for appropriately synchronized high amplitude rhythms
in SCN cellular activities and circadian control of brain, body, and
behavior [30].
The mammalian circadian system was once conceptualized as
consisting of the main SCN pacemaker, whose outputs organized
rhythmic activity in downstream effector sites. Accordingly, this
uniclock view did not afford extra-SCN brain sites or peripheral
tissues with significant endogenous circadian oscillatory capabil-
ities. However, with the determination of the molecular basis of
SCN timekeeping (the so-called core clock genes such as per1-2,
cry1-2, bmal1, etc; [31–33]) and the demonstration that these
genes/proteins are rhythmically expressed in extra-SCN tissues,
including the liver, adrenal and pituitary glands [34–41], this
uniclock model is now known to be incorrect [42,43]. The
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development of fluorescent and bioluminescent reporters of clock
genes and proteins now allows assessment of the capacity of a
tissue to generate circadian rhythms when isolated in culture,
independent of SCN-derived signals [44–46]. Using the mPer2luc
knockin mouse, in which the expression of PER2 is reported by
luciferase, we recently showed that rhythms of PER2 biolumines-
cence are readily measured in the dorsomedial (DMH) and
arcuate (Arc) nuclei, median eminence (ME) and pars tuberalis
(PT) of the mediobasal hypothalamus (MBH; [47]); areas
intimately involved in the control of metabolism [48,49]. This
complemented earlier studies in this mouse model reporting robust
PER2::LUC expression in peripheral tissues including the pituitary
gland [46]. Since VIP is synthesized in the pituitary [50,51], VIP-
ir terminals are present in the MBH [52,53] and VIP binding
sites/VPAC2 mRNA are present in the DMH, Arc, and pituitary
[8,54,55], we investigated whether circadian rhythms in PER2::
LUC bioluminescence in these extra-SCN tissues were compro-
mised by the absence of the VPAC2 receptor.
Methods
Ethics Statement
All experiments were performed in accordance with the UK
Animals (Scientific Procedures) Act of 1986 using procedures
approved by The University of Manchester Review Ethics Panel.
Animals and Behavioral Analysis
For this study, mPer2luc mice [46] were cross-bred with Vipr22/2
mice [13] to generate a PER2::LUC reporter strain that lacked
expression of functional VPAC2 receptors (mPer2
luc6Vipr22/2;
herein referred to as Vipr22/2). Standard mPer2luc mice (expressing
functional VPAC2 receptors) from the University of Manchester
breeding colony were used as controls (WT). All mice used in this
study were adult males on a C57BL/6 background, housed at 20–
22uC and humidity ,40%, with ad libitum access to food and
water.
Animals were initially bred and maintained group housed under
a 12 h light:12 h complete darkness cycle (LD; Zeitgeber time
[ZT] 0 was defined as the time of lights on). Animals contributing
to the LD part of the study were taken directly from these
conditions and culled during the mid-late day phase (mean cull
phase ZT6.761.0 h). Behaviorally screened mice were singly
housed in running wheel-equipped cages (wheel diameter 16 cm)
under LD for at least 7 days then transferred to constant darkness
(DD) for at least 14 days before cull. Analyses of period and
rhythm strength (percentage of variance accounted for by the
rhythm; %V) of wheel-running activity for mice in DD were made
using actograms and Chi2 periodograms created with the Analyze9
software package (Stanford Software Systems, Santa Cruz, CA) on
the final 14 days before cull. Using the onset of wheel-running
activity as a phase marker (circadian time [CT] 12 was defined as
the onset of the daily activity bout), DD mice were culled at times
spanning the circadian cycle to allow assessment of the effect of
culture preparation time on the phase of peak PER2::LUC
expression. Vipr22/2 mice that did not express a significant
circadian rhythm were culled at arbitrary timepoints. Mice were
classified as either rhythmic or expressing multiple low power
rhythmic components (arrhythmic) according to previously
defined criteria [56].
Culture Preparation and Luminometry
Mice were culled by cervical dislocation following isoflurane
anaesthesia (Baxter Healthcare Ltd, Norfolk, UK). SCN, Arc/
ME/PT complex (combined) and DMH were micro-dissected and
cultured as 300 mm thick coronal slices (cut from a consistent
rostro-caudal level for each tissue, based on neuroanatomical
landmarks and the Paxinos and Franklin mouse brain atlas [57] as
previously described [47,58]. Pituitaries were removed by hand
and cultured whole, under identical conditions. Night-vision
goggles were used during DD culls to maintain darkness until
mice had been euthanased and enucleated.
Brain and pituitary cultures were maintained at 37uC in light-
tight incubators (Galaxy R+, RS Biotech, Irvine, Scotland) and
total PER2::LUC bioluminescence emission recorded for at least 7
days using photomultiplier tube (PMT) assemblies (H8259/
R7518P; Hamamatsu, Welwyn Garden City, UK). Emitted
photon counts were integrated for 59 s every 1 min and raw
bioluminescence data were processed by subtracting a 24 h
running mean to remove long term trends (baseline-subtracted)
then smoothed with a 3 h running average. The longitudinal study
design employed here allows sensitive identification of low ampli-
tude rhythms in individual animals, such as those of Vipr22/2
mice. Discontinuous sampling methods, which assess population
level trends across a number of individuals, can fail to detect
significant variation when individuals are not synchronized to one
another or peak-trough amplitude is low [13,17,59].
Gastrin Releasing Peptide and Forskolin Treatments
To investigate the effects of gastrin releasing peptide (GRP) and
adenylate cyclase signaling on circadian expression of PER2::LUC
in WT and Vipr22/2 tissues, cultures were treated with either
100 nM GRP (Tocris Bioscience, Bristol, UK) or 10 mM forskolin
(an adenylate cyclase activator; Sigma, Poole, UK) 3–8 days
following culture preparation. Drugs were administered as com-
plete medium changes to fresh culture medium containing the
drug but otherwise identical to control medium.
Data Analysis and Statistics
Rhythmic bioluminescence traces were assessed by two
experienced, independent researchers, blinded to conditions, to
extract the following parameters: period, amplitude and phase of
peak bioluminescence expression. Period was assessed using peak-
peak and trough-trough durations averaged over as many cycles as
possible for each individual tissue explant, discounting the first
24 h of data. At least one full peak-peak or trough-trough cycle
was assessed of each explant, though in the majority of cases two
or more full cycles were used. Amplitude was measured as the
peak-trough difference 24–48 h after culture preparation from
baseline-subtracted traces and phase was assessed as the time of
the first peak to occur between 24–48 h after culture preparation.
Further, the rate of damping of PER2::LUC bioluminescence
rhythms was assessed as the number of cycles before smoothed
bioluminescence variation reached the amplitude of dark noise
(previously determined for each PMT module). The projected rate
of damping was calculated for cultures that showed obvious
damping of their bioluminescence rhythm but had not fully
damped by the end of data acquisition. Statistically significant
differences between genotypes were determined using unpaired
t-tests performed in Microsoft Excel (p,0.05 required for signi-
ficance). Rayleigh vector plots (custom software designed in house
by Dr T. Brown and El Temps, Dr. A. Dı´ez-Noguera, Barcelona,
Spain) were used to assess the significance of phase clustering of
peak phases in relation to circadian time (CT) or to time from
culture preparation. Responses to forskolin and GRP treatments
were assessed by comparison of amplitude 24 h before and 24 h
after treatments, not including treatment artifacts. Statistical
significance was determined by comparison of amplitude changes
Extra-SCN Rhythms and Phase in Vipr22/2 Mice
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between control and drug treatments (2-way analysis of variance
with a priori pairwise comparisons).
Results
Locomotor Activity Rhythms of Vipr22/2 mice are not
Altered by the PER2::LUC Reporter
mPER2luc (WT) mice behaved in a manner consistent with
previous reports, both for this strain [46] and non-mPER2luc WT
mice (e.g. [20,60,61]). All WT mice (n = 9) entrained to the LD
cycle, confining activity to the dark phase, and all free ran with a
strong circadian rhythm in DD (mean period 23.8260.05 h and
rhythm strength (%V) of 58.5165.34%), starting from the time of
activity onset under LD (Fig. 1A–1B).
Circadian locomotor activity of Vipr22/2 mice was not altered
by the PER2::LUC reporter transgene; mice expressed locomotor
activity rhythms consistent with previous descriptions for non-
mPER2luc Vipr22/2 mice [20,62]. Briefly, Vipr22/2 mice (n = 13)
limited their activity to the dark period of the LD cycle and on
release into DD began activity almost immediately, defining a
large phase advance from the timing of LD activity (Fig. 1C, 1E).
In DD, Vipr22/2 mice expressed the continuum of behavioral
phenotypes common for this genotype, from robustly rhythmic
with a single dominant component of locomotor behavior
Figure 1. Representative Actograms and Periodograms for Individual WT and Vipr22/2 Mice Expressing the PER2::LUC Reporter.
Both WT and Vipr22/2 PER2::LUC-expressing mice synchronize to an LD cycle (A, C, E). WT mice [expressing the PER2::LUC reporter] exhibit a strong,
near 24 h, locomotor activity rhythm in DD, evident on the actogram (A) and from the corresponding high power periodogram peak at ,24 h (B).
Activity recordings and periodograms from Vipr22/2 mice expressing the PER2::LUC reporter display a continuum of behavioral phenotypes in DD,
from strongly rhythmic with a shortened behavioral period (,22.5 h; C–D) to arrhythmic (E–F). Actograms are double-plotted, showing 2 days per
row; shaded areas on actograms represent darkness. Peridograms depict period (hours; x axis) and strength of the rhythm (%V; y axis). Dashed line
indicates p=0.001.
doi:10.1371/journal.pone.0018926.g001
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(Fig. 1C–1D), to apparent arrhythmicity, often with multiple, low
power periodic components (Fig. 1E–1F). Approximately 50% (6/
13) of Vipr22/2 individuals were classified as rhythmic in DD
expressing a mean period of 22.4760.63 h and rhythm strength of
24.1463.70%. Both period and rhythm strength of Vipr22/2 mice
were significantly different to those of WTs (p,0.05 and
p,0.0001, respectively).
Circadian Rhythms of PER2::LUC Expression are
Maintained, but Diminished in the Vipr22/2 SCN
All SCN cultures recorded during this study expressed strong
circadian rhythms of PER2::LUC bioluminescence that remained
robustly rhythmic for the duration of recording (at least 7 days in
vitro; Fig. 2A). The period of rhythms expressed by Vipr22/2 SCN
cultures did not differ from WT SCN rhythms, in cultures
prepared from mice under either LD or DD conditions (both
p.0.05; Table 1). The amplitude of Vipr22/2 SCN rhythms was,
however, significantly lower than that of WT SCN in cultures from
mice housed in both lighting conditions (p,0.01 and p,0.05 for
LD and DD respectively; Table 1; Fig. 2A). No significant
difference was found in either period or amplitude between
behaviorally screened rhythmic and arrhythmic Vipr22/2 mice in
DD (p.0.05; Fig. 2A).
Circadian Rhythms of PER2::LUC Expression are Not
Compromised in the Mediobasal Hypothalamus and
Pituitary of Vipr22/2 Mice
Consistent with earlier work [44,46,47], Arc/ME/PT, DMH,
and pituitary cultures from WT mice showed significant circadian
oscillations in PER2::LUC bioluminescence (Fig. 2B–2D). Exam-
ination of period, amplitude and rate of damping revealed no
significant differences between the rhythms of WT and Vipr22/2
mice expressed in the Arc/ME/PT, DMH or pituitary gland, in
tissue collected from mice housed in either LD or DD (Table 1; all
comparisons p.0.05; Fig. 2B–2D). Further, no significant
differences were found in any of these tissues between the rhythms
Figure 2. Circadian Rhythms in PER2::LUC Expression in WT and Vipr22/2 SCN, MBH and Pituitary. Representative plots of detrended
PER2::LUC bioluminescence expression from SCN (A), Arc/ME/PT complex (B), DMH (C) and pituitary (D) cultures, prepared from behaviorally
rhythmic WT animals and from both behaviorally rhythmic and arrhythmic Vipr22/2 animals all taken from DD free-running conditions. (A) The
amplitudes of both rhythmic and arrhythmic Vipr22/2 SCN PER2::LUC rhythms are significantly lower in than WT SCN rhythms. No differences were
found in rhythm characteristics between rhythmic and arrhythmic Vipr22/2 SCN. (B–D) No differences were observed between the PER2::LUC
rhythms of WT and Vipr22/2mice in any circadian parameter assessed. Traces for WT SCN, Arc/ME/PT and pituitary are plotted as circadian time while
all other tissues are plotted as time from culture preparation.
doi:10.1371/journal.pone.0018926.g002
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expressed by rhythmic and arrhythmic Vipr22/2 mice (all p.0.05;
Fig. 2B–2D).
The Phases of WT and Vipr22/2 PER2::LUC Rhythms in
MBH Tissues, Pituitary and SCN are Differentially Sensitive
to Resetting by Culture Procedure
The phase of peak expression of PER2::LUC was only assessed
for cultures collected from mice housed in DD as these individuals
were culled at a wide range of times throughout the circadian
cycle. This allowed assessment of whether the peak phase of
different tissues from WT and Vipr22/2 mice was associated with a
particular CT phase or was reset by cull/culture procedure and
expression peaked the same number of hours after cull regardless
of the CT phase of cull.
Overall, WT SCN peak phase was significantly associated with
CT (p,0.00001; Fig. 3A); rhythms peaked at a mean phase of
CT12.960.5, with a slightly earlier phase (,CT11–12) observed
in cultures from mice culled during the middle of the circadian
day, and a slightly later phase (,CT14) observed in cultures
prepared at other times. Vipr22/2 SCN, however, were reset by
cull/culture procedure and PER2::LUC rhythms consistently
peaked at ,31 h after cull (30.760.3 h; SCN peak phases from
behaviorally rhythmic (30.860.5 h) and arrhythmic (30.660.4 h)
Vipr22/2 mice combined), regardless of the circadian phase of cull
and culture preparation. Indeed, Rayleigh analysis revealed
Vipr22/2 SCN peak phase from rhythmic individuals to correlate
significantly with time of cull (p,0.0001) and not CT (Fig. 3A).
Behaviorally arrhythmic Vipr22/2 mice were not included in these
Rayleigh analyses as CT phase could not be calculated for these
individuals, however, a separate analysis of the peak phase for
arrhythmic Vipr22/2 SCN cultures also revealed a significant
association with time from cull (Fig. 3A; p,0.0001).
Similarly to SCN cultures, WT Arc/ME/PT expressed peak
levels of PER2::LUC at a consistent circadian phase
(CT19.960.7; Rayleigh correlation with CT: p,0.0001) and were
not reset by cull/culture procedure (Fig. 3B). Vipr22/2 Arc/ME/
PT cultures, as for Vipr22/2 SCN, were reset by cull/culture and
peaked 31.860.7 h following cull (behaviorally rhythmic
(32.560.9 h) and arrhythmic (31.1 h61.4 h) individuals com-
bined). Vipr22/2 Arc/ME/PT peak phase for both rhythmic
(p,0.005) and arrhythmic (p,0.05) mice correlated significantly
with time from cull (Fig. 3B). While pituitary cultures from WT
mice consistently expressed peak levels of PER2::LUC expression
at CT17.761.4 h (Rayleigh correlation with CT: p,0.01), the
phase of Vipr22/2 pituitaries differed widely between individuals
Table 1. Bioluminescence Data for Circadian Parameters of WT and Vipr22/2 Tissues.
LD DD
WT Vipr22/2 WT Vipr22/2
SCN
Number of cultures n = 10 n= 13 n= 9 n = 13
% Rhythmic 100% 100% 100% 100%
Period (h) 24.2460.16 23.8160.14 24.5460.22 24.4160.19
Rate of Damping (d) N/A N/A N/A N/A
Amplitude (arbitrary units) 31296446 14656243** 658361628 32556529*
Arc/ME/PT
Number of cultures n = 8 n= 13 n= 9 n = 13
% Rhythmic 88% 85% 89% 100%
Period (h) 23.3460.54 23.4560.28 23.1460.21 24.1160.56
Rate of Damping (d) 4.660.6 4.060.6 4.060.7 3.360.5
Amplitude (arbitrary units) 169631 145622 126630 151624
DMH
Number of cultures n = 7 n= 12 n= 9 n = 13
% Rhythmic 71% 83% 100% 100%
Period (h) 25.0260.92 24.0760.65 25.2260.97 24.8660.62
Rate of Damping (d) 2.260.4 2.160.3 2.760.7 2.160.2
Amplitude (arbitrary units) 100635 110620 130624 111615
Pituitary
Number of cultures n = 8 n= 13 n= 9 n = 8
% Rhythmic 100% 100% 100% 100%
Period (h) 23.2860.34 23.6060.12 23.5360.27 23.6360.22
Rate of Damping (d) N/A N/A N/A N/A
Amplitude (arbitrary units) 518061197 47276736 36256690 24866879
NOTE: LD= tissue collected from mice housed under a 12 h:12 h light:dark cycle; DD= tissue collected from mice housed in constant darkness; WT=mPer2luc-expressing
wild type mice; Vipr22/2=mPer2luc-expressing mice lacking functional expression of the VPAC2 receptor gene.
* = significant difference to WT under DD at p,0.05;
** = significant difference to WT under LD at p,0.01.
Values are presented as mean 6 SEM.
doi:10.1371/journal.pone.0018926.t001
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and was not consistently associated with either a particular
circadian phase or duration of time following cull (Rayleigh
associations with CT (for behaviorally rhythmic individuals only)
and cull time (rhythmic and arrhythmic individuals separately), all
p.0.05). DMH tissue from both WT and Vipr22/2 mice reset to
,30 h after cull (29.761.2 h and 30.160.5 h, respectively),
regardless of the CT cull phase or behavioral rhythmicity of the
animal (Rayleigh correlation with time from cull p,0.05, p,0.005
and p,0.005, respectively for WT, behaviorally rhythmic and
behaviorally arrhythmic Vipr22/2 mice).
Circadian Rhythms of PER2::LUC Expression in MBH
Tissues, Pituitary and SCN are Differentially Affected by
Treatments with Forskolin and Gastrin Releasing Peptide
To investigate the health of tissues after rhythms had damped,
cultures were treated with the adenylate cyclase activator, forskolin
(10 mM), previously shown to boost rhythms in cultured circadian
oscillator tissues [44]. Forskolin treatment induced robust increases
in rhythm amplitude in tissues that previously showed either a
circadian deficit due to altered VIP-VPAC2 signaling (Vipr2
2/2
SCN; p,0.005; Table 2), or demonstrated rapid damping of
oscillations (WT and Vipr22/2 Arc/ME/PT, p,0.005 and
p,0.0005, respectively; WT and Vipr22/2 DMH, p,0.01 and
p,0.005, respectively; Table 2). More robustly rhythmic tissues
(WT SCN, WT and Vipr22/2 pituitary gland) did not show
significant increases in rhythm amplitude following forskolin
treatment (Table 2), presumably as these tissues had not yet
significantly damped at the time of treatment and/or did not suffer
any inherent rhythm abnormalities associated with a lack of
VPAC2 receptors.
GRP treatment to Vipr22/2 SCN tissue in vitro has been shown
to boost and resynchronize rhythms [27,29] and GRP receptors
are expressed in the pituitary gland and arcuate nucleus [63,64].
We, therefore, investigated whether GRP treatments would induce
similar responses from oscillators in the MBH and pituitary.
Surprisingly, neither WT nor Vipr22/2 SCN rhythms were
markedly improved by treatment with 100 nM GRP (both
p.0.05; Table 2, Fig. 4A). The amplitude of Arc/ME/PT
rhythms, however, was increased by treatment with GRP (p,0.05
for both WT and Vipr22/2 tissue; Table 2, Fig. 4B). Interestingly,
though GRP receptor expression has not been reported in the
DMH, WT DMH cultures showed an increase in rhythm
amplitude in response to GRP treatment (p,0.05; Table 2,
Fig. 4C) while Vipr22/2 DMH cultures failed to do so. The
amplitude change of rhythms expressed by WT pituitaries in
response to GRP was not significantly different to control
treatments (Table 2, Fig. 4D), however, this lack of significance
resulted from control treatments inducing an increase in amplitude
in 3 of 5 cultures. Indeed, GRP treatments did induce a significant
increase in amplitude in WT pituitary cultures (post-treatment
amplitude vs. pre-treatment amplitude p,0.05; Table 2, Fig. 4D)
and the mean increase in amplitude in response to GRP treatment
was 665% of the mean control treatment-induced response.
Conversely, neither GRP nor control treatment increased the
amplitude of PER2::LUC expression in Vipr22/2 pituitaries
(p.0.05; Table 2, Fig. 4D).
Discussion
Clock Gene Rhythms Persist in the Vipr22/2 MBH and
Pituitary
While the SCN innervates the MBH region [53], endogenous
rhythms in clock gene expression are present in vitro in the MBH
and pituitary gland [44,46,47,65], tissues critical for the regulation
of metabolism [49]. Signaling via the VPAC2 receptor is essential
for the generation of high amplitude synchronized SCN clock gene
rhythms [13,26,27] and for appropriate temporal control of
Figure 3. Rayleigh Plots Showing the Effect of Culture
Preparation on Peak Phase of PER2::LUC Expression in SCN
and Arc/ME/PT. Plots show peak PER2::LUC phase for WT and Vipr22/2
SCN and Arc/ME/PT plotted as either circadian time (CT; based on
behavioral rhythms) or time of peak bioluminescence after culture
preparation (Time From Culture). CT plots include data from behaviorally
rhythmic mice only (black data points, arrow and dashed line) while time
from culture plots show data both from behaviorally rhythmic (black) and
arrhythmic (red) mice, analyzed separately. Black data points from
behaviorally rhythmic mice on CT plots and time from cull plots are
directly comparable. Red points from arrhythmic Vipr22/2 mice are
included for subjective comparison. Both SCN and Arc/ME/PT from WT
mice express peak PER2::LUC bioluminescence at a consistent circadian
phase, regardless of cull/culture time (peak phase is correlatedwith CT not
with time from culture). However, Vipr22/2 SCN and Arc/ME/PT always
peak the same number of hours after culture preparation, showing these
tissues to be reset by this process (peak phase correlated with time from
culture not CT. Note that phase is well clustered for WT CT plots (upper
left of panelsA and B) and Vipr22/2 time from culture plots (lower right of
panels A and B). Filled circles indicate the phase of peak bioluminescence
in individual cultures. The direction of an arrow indicates the mean phase
vector and its length shows significance relative to the (p=0.05)
significance threshold indicated by the inner broken circle. Boxes
surrounding arrow heads show variance of phase between cultures.
doi:10.1371/journal.pone.0018926.g003
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behavior and metabolism [18,20]. Here, we demonstrate that,
despite known alterations of circadian function in Vipr22/2 mice,
the lack of VPAC2 receptors does not alter period, amplitude or
rate of damping of rhythms in PER2 expression in the Vipr22/2
MBH and pituitary. These rhythms were observed in slice cultures
from mice housed in LD and persisted in tissues collected from
mice housed in DD, despite the behavioral arrhythmicity of
,50% of Vipr22/2 mice in constant conditions. This study
provides the first description of extra-SCN neural oscillators in
mice lacking either VIP or VPAC2, while our demonstration of
rhythm maintenance in the Vipr22/2 pituitary gland concurs with
a previous report of peripheral oscillations in the liver and heart of
these mice [66].
Vipr22/2 SCN Phase is Reset by Culture Procedure:
Oscillator Strength Determines the Ability of Tissues to
Maintain In Vivo Phase when Cultured In Vitro
Consistent with previous investigations, both in our laboratory
and elsewhere, Vipr22/2 SCN were found to express significantly
lower amplitude clock gene oscillations than WT SCN [25–27]. In
contrast, the MBH and pituitary do not show this decrease in
amplitude. Rather more surprisingly, we found an alteration in the
ability of Vipr22/2 SCN tissue to maintain a consistent circadian
phase when cultured in vitro. WT SCN cultures expressed peak
levels of PER2::LUC expression at a predictable projected CT
phase, consistent with previous in vivo and in vitro investigations of
per2/PER2 expression [47,67–71]. Further, the earlier peak phase
we observed for WT cultures prepared during the circadian day is
consistent with a small phase advance of rhythms in cultures
prepared at this time [58,72].
Conversely, the rhythms of SCN cultures from Vipr22/2 mice
were reset by cull/culture procedure and consistently peaked at
the same time after culture preparation, regardless of the circadian
phase at which this procedure was performed, illustrating the
critical role of VIP-VPAC2 signaling in the maintenance of robust
SCN function. These data suggest that while the strong rhythm
generating properties of the WT SCN, at the unicellular and
network levels, are sufficient to maintain in vivo phase, the
diminished circadian capabilities of the relatively weak and
disorganized Vipr22/2 SCN are unable to resist the phase-shifting
influences associated with culture preparation. This presents an
interesting parallel with a recent description of in vitro PER2::LUC
phase in embryonic mouse liver [73]. Here, the authors find the
phase of embryonic liver cultures to be determined by cull/culture
time, while the phase of PER2::LUC rhythms in maternal liver is
determined by external Zeitgeber time.
WT and Vipr22/2 MBH and Pituitary Oscillators are
Differentially Sensitive to Phase Resetting by Culture
Procedure
The tendency for stronger oscillators to maintain phase and
weaker oscillators to reset to cull time is also seen across the Arc/
ME/PT, DMH and pituitary oscillators. In WT tissue, the
stronger of the MBH areas investigated here, the Arc/ME/PT,
maintains an in vitro phase similar to a prior report of the
expression of per2 in these areas [74], whereas the weaker oscillator
contained in the DMH is reset by cull/culture. Similarly, WT
pituitary, which contains a strong oscillator of comparable strength
and robustness to the WT SCN (based on rhythm amplitude and a
lack of damping), maintains a consistent in vitro CT phase of peak
PER2::LUC expression. Vipr22/2 pituitary, however, appears to
neither maintain a steady phase predicted by locomotor rhythms,
nor fully reset according to cull/culture time. This lack of resetting
of the Vipr22/2 pituitary differs from the properties of the Vipr22/2
SCN and indicates a reduced importance of VPAC2 signaling for
the maintenance of pituitary rhythms – supported by the absence of
any significant alteration to period, amplitude or rate of damping in
Vipr22/2 pituitary.
While the phase of Vipr22/2 DMH responds to culturing in a
similar fashion to WT DMH tissue, it is intriguing that WT and
Vipr22/2 Arc/ME/PT and pituitary are differentially sensitive to
the phase-resetting stimuli associated to culture preparation. This
inability of Vipr22/2 Arc/ME/PT and pituitary to maintain an in
vitro phase that correlates with the phase of behavioral rhythms is
surprising given that these tissues show no alteration in period,
amplitude or rate of damping of PER2::LUC expression. This
raises the possibility that VPAC2 signaling within these oscillators
impacts on other aspects of rhythm strength/robustness that we
have not detected here. Further, bioluminescence imaging studies
and microdissections of the individual rhythmic components of the
Arc/ME/PT complex (Arc, ME, PT and the ependymal cell layer
of the 3rd ventricle; [47]) will be necessary to elucidate the relative
contribution of these oscillators to both rhythmicity of the Arc/
ME/PT complex in Vipr22/2 mice and its increased sensitivity to
Table 2. Bioluminescence Amplitude Data for Responses of WT and Vipr22/2 Tissues to Control and GRP Treatments.
WT Vipr22/2
Control Forskolin GRP Control Forskolin GRP
SCN 212066399 (4) 220806417 (3) 214776430 (6) 22256225 (4) 15716409*** (4) 24086339 (4)
Arc 220.6612.3 (4) 143636*** (4) 61.8626.2* (4) 234.2622.8 (6) 448692**** (4) 59.5629.6 * (4)
DMH 210.0610.7 (4) 86629** (5) 91.7648.1* (5) 20.763.2 (4) 133629*** (4) 7.869.4 (4)
Pituitary 1056215 (4) 27016658 (5) 6956226{ (5) 24776461 (4) 213676582 (4) 22436631 (4)
NOTE: Values are presented as mean amplitude change from pre- to post-treatment 6 SEM. All treatments were delivered to tissue collected from mice housed under a
12 h:12 h light:dark cycle. WT=mPer2luc-expressing wild type mice; Vipr22/2=mPer2luc-expressing mice lacking functional expression of the VPAC2 receptor gene.
* = significant difference to control treatment at p,0.05;
** = significant difference to control treatment at p,0.01;
*** = significant difference to control treatment at p,0.005;
**** = significant difference to control treatment at p,0.0005;
{=GRP-treated WT pituitary responses were not significantly different to control responses (as some control-treated WT pituitaries showed an increase in rhythm
amplitude), however, GRP did induce a significant increase (p,0.05) in post-treatment vs. pre-treatment amplitude.
Negative values arise due to the normal reduction in rhythm amplitude over time (e.g. see Figs. 2 and 4) when treatments do not induce an increase in amplitude.
Numbers in brackets indicate ‘n’ contributing to that data value.
doi:10.1371/journal.pone.0018926.t002
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phase-resetting compared to WT tissue. The increased sensitivity
of Vipr22/2 Arc/ME/PT and pituitary oscillators to stimuli
associated with culture preparation presents an intriguing parallel
with the increased sensitivity of mice lacking VIP-VPAC2 signaling
to photic stimuli [17,75].
Variable Responses of WT and Vipr22/2 Tissue to GRP
Treatment
Responses to GRP treatment were variable, with no consistent
genotype differences across the tissues examined, or tissue
differences between genotypes. Surprisingly, neither WT nor
Vipr22/2 SCN cultures responded to GRP treatment with an
increase in the amplitude of PER2 expression, as has been shown
previously [27,29]. These studies, however, differ in crucial
technical details to the current investigation, measuring electrical
activity with chronic GRP infusion and measuring per1 expression
in neonatal tissue, respectively. Indeed, the failure of GRP to boost
rhythm amplitude of clock gene expression in vitro has previously
been reported in cultured extra-SCN brain tissue [76]. Our
observation of increased WT DMH rhythm amplitude following
GRP treatment is of note given the lack of previous reports of
GRP binding sites/GRP receptor expression in the DMH. This
response is presumably mediated by previously undetected
bombesin-like peptide receptors [77] in this area.
Summary
The data presented here demonstrate that SCN and extra-SCN
circadian oscillations are maintained in the absence of VIP-
VPAC2 signaling. However, the Vipr2
2/2 tissues assessed here are
differentially capable, compared to WT tissues, of maintaining a
consistent circadian phase when cultured in vitro. Most surprisingly,
the phase of PER2 oscillations in Vipr22/2 SCN is reset by culture
Figure 4. Rhythm Amplitude of PER2::LUC Expression in WT and Vipr22/2 SCN, MBH and Pituitary are Differentially Affected by GRP
Treatment. Representative plots of detrended PER2::LUC bioluminescence expression from WT and Vipr22/2 SCN (A), Arc/ME/PT complex (B), DMH
(C) and pituitary (D) cultures, prepared from mice housed under LD conditions. (A) GRP treatment failed to increase rhythm amplitude in both WT
and Vipr22/2 SCN. (B) Both WT and Vipr22/2 Arc/ME/PT responded to GRP treatment with an increase in rhythm amplitude. (C) GRP application
increased the amplitude of DMH rhythms in WT tissue but not Vipr22/2. (D) WT pituitaries responded to GRP application with an increase in rhythm
amplitude (though see results text and Table 2 note) while Vipr22/2 pituitaries failed to do so. Traces for WT SCN, Arc/ME/PT and pituitary are plotted
as circadian time while all other tissues are plotted as time from culture preparation. Note treatment artefacts immediately after GRP application to
cultures.
doi:10.1371/journal.pone.0018926.g004
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preparation. Despite the maintenance of period, amplitude and
rate of damping in the Arc/ME/PT, DMH and pituitary, the
differential resetting effects of culture preparation on WT and
Vipr22/2 phase in these areas presumably reflects circadian
deficiencies not assessed here which may contribute towards the
aberrant behavior and metabolism associated with Vipr22/2
animals.
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